Stage IIIB Prostate Cancer AJCC v8
29
7
12
11
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.3%
3 terminated out of 29 trials
78.6%
-7.9% vs benchmark
3%
1 trials in Phase 3/4
27%
3 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (29)
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
RElugolix VErsus LeUprolide Cardiac Trial
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer